During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease.

Summit Therapeutics (NASDAQ:SMMT) shares soar 51% after its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49% compared to Merck’s (NYSE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...